中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
9期
1536-1537,1538
,共3页
益坤宁颗粒%替勃龙%帕罗西汀%更年期综合征%Kupperman评分%激素水平
益坤寧顆粒%替勃龍%帕囉西汀%更年期綜閤徵%Kupperman評分%激素水平
익곤저과립%체발룡%파라서정%경년기종합정%Kupperman평분%격소수평
Yikunning granules%Tibolone%Paroxetine%Menopausal syndrome%Kupperman score%Hormone level
目的：探讨益坤宁颗粒联合替勃龙、帕罗西汀治疗更年期综合征的临床疗效和安全性。方法：150例更年期综合征患者随机分为对照组和观察组各75例,对照组予替勃龙片2.5 mg,po,qd,帕罗西汀片20 mg,po,qd,观察组再对照组基础上加用益坤宁颗粒3 g,po,tid。3个月后采用改良Kupperman评分评价两组患者临床症状,比较两组血清雌二醇( E2)、促黄体生成素(LH)、促卵泡生成素(FSH)、泌乳素(PRL)、孕酮(P)水平变化,观察两组药品不良反应。结果：治疗后,两组患者改良Kupper-man评分多数指标较治疗前有不同程度改善(P<0.05),且观察组潮热出汗、焦虑、忧郁、心悸及总分等指标改善优于对照组(P<0.05)；两组患者E2增高,LH、FSH降低(P<0.05)；PRL、P无明显改变(P>0.05),且观察组E2、LH、FSH水平均较对照组改善更明显(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论：益坤宁颗粒联合替勃龙、帕罗西汀治疗更年期综合征能有效改善患者临床症状和性激素水平,效果优于西药治疗。
目的：探討益坤寧顆粒聯閤替勃龍、帕囉西汀治療更年期綜閤徵的臨床療效和安全性。方法：150例更年期綜閤徵患者隨機分為對照組和觀察組各75例,對照組予替勃龍片2.5 mg,po,qd,帕囉西汀片20 mg,po,qd,觀察組再對照組基礎上加用益坤寧顆粒3 g,po,tid。3箇月後採用改良Kupperman評分評價兩組患者臨床癥狀,比較兩組血清雌二醇( E2)、促黃體生成素(LH)、促卵泡生成素(FSH)、泌乳素(PRL)、孕酮(P)水平變化,觀察兩組藥品不良反應。結果：治療後,兩組患者改良Kupper-man評分多數指標較治療前有不同程度改善(P<0.05),且觀察組潮熱齣汗、焦慮、憂鬱、心悸及總分等指標改善優于對照組(P<0.05)；兩組患者E2增高,LH、FSH降低(P<0.05)；PRL、P無明顯改變(P>0.05),且觀察組E2、LH、FSH水平均較對照組改善更明顯(P<0.05)。兩組藥品不良反應髮生率比較,差異無統計學意義(P>0.05)。結論：益坤寧顆粒聯閤替勃龍、帕囉西汀治療更年期綜閤徵能有效改善患者臨床癥狀和性激素水平,效果優于西藥治療。
목적：탐토익곤저과립연합체발룡、파라서정치료경년기종합정적림상료효화안전성。방법：150례경년기종합정환자수궤분위대조조화관찰조각75례,대조조여체발룡편2.5 mg,po,qd,파라서정편20 mg,po,qd,관찰조재대조조기출상가용익곤저과립3 g,po,tid。3개월후채용개량Kupperman평분평개량조환자림상증상,비교량조혈청자이순( E2)、촉황체생성소(LH)、촉란포생성소(FSH)、비유소(PRL)、잉동(P)수평변화,관찰량조약품불량반응。결과：치료후,량조환자개량Kupper-man평분다수지표교치료전유불동정도개선(P<0.05),차관찰조조열출한、초필、우욱、심계급총분등지표개선우우대조조(P<0.05)；량조환자E2증고,LH、FSH강저(P<0.05)；PRL、P무명현개변(P>0.05),차관찰조E2、LH、FSH수평균교대조조개선경명현(P<0.05)。량조약품불량반응발생솔비교,차이무통계학의의(P>0.05)。결론：익곤저과립연합체발룡、파라서정치료경년기종합정능유효개선환자림상증상화성격소수평,효과우우서약치료。
Objective:To explore the clinical effect and safety of Yikunning granules combined with tibolone and paroxetine in the treatment of female patients with menopausal syndrome. Methods:Totally 150 female patients with menopausal syndrome were randomly divided into the control group (75 cases) and the study group (75 cases). The control group was orally given tibolone (2. 5mg,po,qd) and paroxetine tablets (20mg,po,qd), and the study group was treated with Yikunning granules additionally (3g,po,tid). After 3-month treatment, the modified Kupperman score was used to evaluate the clinical symptoms, radioimmunoassay was used to detect the serum lev-els of estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL) and progesterone (P), and the adverse reactions were recorded. Results:After the treatment, most of the indices in the modified Kupperman score were improved in the two groups (P<0. 05). In the study group, such symptoms as hot flashes and perspiration, anxiety, depression and palpitations, and the general score were improved more notable than those in the control group(P<0. 05). After the treatment, serum levels of E2 was in-creased, while FSH and PRL were decreased(P<0. 05), and PRL and P were unchanged (P>0. 05). The improvement of E2, LH and FSH in the study group was better than that in the control group (P<0. 05). There was no significant difference in the adverse reactions between the two groups (P<0. 05). Conclusion:Yikunning granules combined with tibolone and paroxetine show good effectiveness in the treatment of menopausal syndrome with improved clinical symptom and sex hormone levels, which is worthy of promotion.
